Patents by Inventor Hiroshi Mizokami
Hiroshi Mizokami has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8647634Abstract: A recombinant avian infectious coryza vaccine and a process for preparing the same are provided. A process for preparing a recombinant avian infectious coryza vaccine which comprises step of constructing E. coli that may produce as an inclusion body a fusion peptide consisting of peptides derived from outer-membrane protein of Avibacterium paragarinarum serotype A and serotype C, step of culturing said E. coli and collecting and purifying inclusion body from culture, and step of preparing a preparation comprising said purified inclusion body, and an avian infectious coryza vaccine comprising as an active ingredient the fusion peptide. A linker sequence may be inserted between the respective peptides comprising the fusion peptide. For the peptide derived from the serotypes A and C, an amino acid sequence region of Region 2 or its vicinity responsible for protection from infection may be used.Type: GrantFiled: December 24, 2009Date of Patent: February 11, 2014Assignee: The Chemo-Sero-Therapeutic Research InstituteInventors: Ryuichi Sakamoto, Susumu Baba, Masashi Sakaguchi, Hiroshi Mizokami
-
Publication number: 20130183330Abstract: A recombinant avian infectious coryza vaccine and a process for preparing the same are provided. A process for preparing a recombinant avian infectious coryza vaccine which comprises step of constructing E. coli that may produce as an inclusion body a fusion peptide consisting of peptides derived from outer-membrane protein of Avibacterium paragarinarum serotype A and serotype C, step of culturing said E. coli and colleting and purifying inclusion body from culture, and step of preparing a preparation comprising said purified inclusion body, and an avian infectious coryza vaccine comprising as an active ingredient the fusion peptide. A linker sequence may be inserted between the respective peptides comprising the fusion peptide. For the peptide derived from the serotypes A and C, an amino acid sequence region of Region 2 or its vicinity responsible for protection from infection may be used.Type: ApplicationFiled: September 14, 2012Publication date: July 18, 2013Applicant: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTEInventors: Ryuichi SAKAMOTO, Susumu Baba, Masashi Sakaguchi, Hiroshi Mizokami
-
Patent number: 8332159Abstract: A method of enhancing the efficacy of a monoclonal antibody preparation wherein antigens from patients are tested for their reactivity with the antibody. An amino acid sequence of an expressed protein is deuced from a nucleotide sequence determined by isolation and analysis of a target molecule gene in a biopsy from a patient. This is compared with the previously determined amino acid sequence recognized by the monoclonal antibody preparation in order to assess the fitness of patients for administration of the monoclonal antibody preparation.Type: GrantFiled: February 18, 2004Date of Patent: December 11, 2012Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Toshio Murakami, Hirofumi Higuchi, Keiichi Makizumi, Toshihiro Maeda, Hiroshi Mizokami
-
Publication number: 20120003257Abstract: A recombinant avian infectious coryza vaccine and a process for preparing the same are provided. A process for preparing a recombinant avian infectious coryza vaccine which comprises step of constructing E. coli that may produce as an inclusion body a fusion peptide consisting of peptides derived from outer-membrane protein of Avibacterium paragarinarum serotype A and serotype C, step of culturing said E. coli and colleting and purifying inclusion body from culture, and step of preparing a preparation comprising said purified inclusion body, and an avian infectious coryza vaccine comprising as an active ingredient the fusion peptide. A linker sequence may be inserted between the respective peptides comprising the fusion peptide. For the peptide derived from the serotypes A and C, an amino acid sequence region of Region 2 or its vicinity responsible for protection from infection may be used.Type: ApplicationFiled: December 24, 2009Publication date: January 5, 2012Applicant: The Chemo-Sero-Therapeutic Research InstituteInventors: Ryuichi Sakamoto, Susumu Baba, Masashi Sakaguchi, Hiroshi Mizokami
-
Patent number: 7667009Abstract: A method for purifying a modified major mite allergen obtained by the genetic recombination technique and a purified modified major mite allergen obtained by said method for purification are provided.Type: GrantFiled: April 14, 2004Date of Patent: February 23, 2010Assignee: Juridical Foundation the Chemo-Sero-Therapeutic Research InstituteInventors: Satoshi Koyanagi, Kenjiro Kawatsu, Toshio Murakami, Yoshinobu Miyatsu, Toshihiro Maeda, Hiroshi Mizokami
-
Patent number: 7531631Abstract: The present invention herein discloses a method for purifying human serum albumin, which is characterized in that it comprises the steps of heat-treating a human serum albumin-containing solution including impurities originated from a host cell, in the presence of a divalent cation such as calcium ion, magnesium ion, nickel ion, cobalt ion, iron ion and zinc ion to thus selectively allow the impurities to undergo agglutination. The present invention also provides the highly purified human serum albumin prepared by the foregoing method.Type: GrantFiled: July 20, 2006Date of Patent: May 12, 2009Assignee: Juridical Foundation the Chemoserotherapeutic Research InstituteInventors: Shinichi Shibata, Kazuyuki Nakashima, Tetsurou Tanabe, Yoshinobu Miyatsu, Hiroshi Mizokami
-
Publication number: 20080113424Abstract: A method for purifying a modified major mite allergen obtained by the genetic recombination technique and a purified modified major mite allergen obtained by said method for purification are provided.Type: ApplicationFiled: April 14, 2004Publication date: May 15, 2008Applicant: Juridicical Foundation the Chemo-Sero-Therapeutic Research InstituteInventors: Satoshi Koyanagi, Kenjiro Kawatsu, Toshio Murakami, Yoshinobu Miyatsu, Toshihiro Maeda, Hiroshi Mizokami
-
Publication number: 20070065906Abstract: A heterologous protein free from an inducer and a method for producing said protein are provided. A method for producing a heterologous protein which comprises the step of optionally culturing at low temperature recombinant E. coli cells expressing a heterologous protein under control of a promoter capable of inducing expression through temperature shift and then culturing at high temperature said recombinant E. coli cells in the absence of an inducer to thereby allow for expression of said heterologous protein, or the step of culturing at high temperature said recombinant E. coli cells to thereby simultaneously allow for both cell proliferation and expression of said heterologous protein, and the heterologous protein obtained by said method that is free from an inducer. Such heterologous protein may include a major mite allergen, a secretary macrophage toxin from Actinobacillus pleuropneumoniae and a surface protective antigen (SpaA) of Erysipelothrix rhusiopathiae.Type: ApplicationFiled: February 20, 2004Publication date: March 22, 2007Applicant: JURIDICAL FOUNDATION the CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTEInventors: Satoshi Koyanagi, Keishin Sugawara, Yoshinobu Miyatsu, Toshio Murakami, Toshihiro Maeda, Hiroshi Mizokami
-
Publication number: 20060280751Abstract: A method for enhancing efficacy of a monoclonal antibody preparation is provided wherein antigens from patients are tested for their reactivity with said antibody. In accordance with the method of the invention, an amino acid sequence of an expressed protein is deduced from a nucleotide sequence determined by isolation and analysis of a target molecule gene in biopsy from patients and is compared with the previously determined amino acid sequence recognized by said monoclonal antibody preparation to thereby assess fitness of patients for administration of said monoclonal antibody preparation.Type: ApplicationFiled: February 18, 2004Publication date: December 14, 2006Inventors: Toshio Murakami, Hirofumi Higuchi, Keiichi Makizumi, Toshihiro Maeda, Hiroshi Mizokami
-
Publication number: 20060258850Abstract: The present invention herein discloses a method for purifying human serum albumin, which is characterized in that it comprises the steps of heat-treating a human serum albumin-containing solution including impurities originated from a host cell, in the presence of a divalent cation such as calcium ion, magnesium ion, nickel ion, cobalt ion, iron ion and zinc ion to thus selectively allow the impurities to undergo agglutination. The present invention also provides the highly purified human serum albumin prepared by the foregoing method.Type: ApplicationFiled: July 20, 2006Publication date: November 16, 2006Inventors: Shinichi Shibata, Kazuyuki Nakashima, Tetsurou Tanabe, Yoshinobu Miyatsu, Hiroshi Mizokami
-
Patent number: 7001885Abstract: Multimers of human serum albumin are removed from a solution of human serum albumin containing the multimers by bringing the human serum albumin solution into contact with an anion-exchanger equilibrated with a buffer containing a salt in a concentration ranging from 10 to 150 mM and having a pH value ranging from 5 to 9.5.Type: GrantFiled: June 20, 2002Date of Patent: February 21, 2006Assignee: Juridical Foundation the Chemo-Sero-Therapeutic Research InstituteInventors: Satoshi Adachi, Hiroshi Mizokami, Yoshitaka Tajima, Yoshinobu Miyatsu, Toshinobu Nouchi, Yoshitaka Ushio
-
Patent number: 6908749Abstract: A method for preparing human serum albumin comprises the step of heat-treating a human serum albumin solution containing contaminants at a pH value in the proximity to the isoelectric point of the contaminants.Type: GrantFiled: June 20, 2002Date of Patent: June 21, 2005Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Toshinobu Nouchi, Hiroshi Mizokami, Yoshitaka Tajima, Yoshinobu Miyatsu, Masahiro Sakaguchi, Kazunari Yagi
-
Patent number: 6869934Abstract: The present invention relates to a method for purifying a calcium ion-binding protein by cation exchange chromatography. The present invention provide a method for isolating and purifying a calcium ion-binding protein in a simple and efficient manner from a liquid sample containing a calcium ion-binding protein and contaminants without any pretreatment such as addition of a chelating agent. More specifically, the present invention relates to a method for purifying a calcium ion-binding protein which comprises contacting said protein with a cation exchange carrier in the presence of calcium ions to let the said protein be adsorbed to the carrier, and after washing, eluting said protein, and to a calcium ion-binding protein having substantially no contaminants obtained by the method of the present invention.Type: GrantFiled: July 18, 2001Date of Patent: March 22, 2005Assignees: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute, Kowa Company, Ltd.Inventors: Hiroshi Mizokami, Shinichi Furukawa, Keishin Sugawara, Tatsufumi Onchi, Kazuhiro Komatsu, Satoshi Koyanagi, Hideo Yoshizaki
-
Publication number: 20050059805Abstract: The present invention relates to a method for purifying a calcium ion-binding protein by cation exchange chromatography. The present invention provide a method for isolating and purifying a calcium ion-binding protein in a simple and efficient manner from a liquid sample containing a calcium ion-binding protein and contaminants without any pretreatment such as addition of a chelating agent. More specifically, the present invention relates to a method for purifying a calcium ion-binding protein which comprises contacting said protein with a cation exchange carrier in the presence of calcium ions to let the said protein be adsorbed to the carrier, and after washing, eluting said protein, and to a calcium ion-binding protein having substantially no contaminants obtained by the method of the present invention.Type: ApplicationFiled: September 21, 2004Publication date: March 17, 2005Inventors: Hiroshi Mizokami, Shinichi Furukawa, Keishin Sugawara, Tatsufumi Onchi, Kazuhiro Komatsu, Satoshi Koyanagi, Hideo Yoshizaki
-
Publication number: 20030027991Abstract: A method for converting a multimer of human serum albumin into monomers thereof comprises the step of treating the multimer with an alkaline solution. This method permits the efficient and quite simple conversion of human serum albumin multimers into monomers thereof at a low cost.Type: ApplicationFiled: June 21, 2002Publication date: February 6, 2003Applicant: Juridical Fdn. The Chemo-Sero-Therap. Res. Ctr.Inventors: Toshinobu Nouchi, Hiroshi Mizokami, Yoshitaka Tajima, Hiroyuki Yokote, Satoshi Adachi, Yoshinobu Miyatsu, Tetsuro Tanabe, Yoshitaka Ushio, Shinichi Shibata
-
Publication number: 20020182680Abstract: A method for preparing human serum albumin comprises the step of heat-treating a human serum albumin solution containing contaminants at a pH value in the proximity to the isoelectric point of the contaminants.Type: ApplicationFiled: June 20, 2002Publication date: December 5, 2002Applicant: Juridical Fdn. The Chemo-Sero-Therap. Res. Ctr.Inventors: Toshinobu Nouchi, Hiroshi Mizokami, Yoshitaka Tajima, Yoshinobu Miyatsu, Masahiro Sakaguchi, Kazunari Yagi
-
Publication number: 20020183492Abstract: Multimers of human serum albumin are removed from a solution of human serum albumin containing the multimers by bringing the human serum albumin solution into contact with an anion-exchanger equilibrated with a buffer containing a salt in a concentration ranging from 10 to 150 mM and having a pH value ranging from 5 to 9.5.Type: ApplicationFiled: June 20, 2002Publication date: December 5, 2002Applicant: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Satoshi Adachi, Hiroshi Mizokami, Yoshitaka Tajima, Yoshinobu Miyatsu, Toshinobu Nouchi, Yoshitaka Ushio
-
Publication number: 20020169294Abstract: The present invention relates to a method for purifying a calcium ion-binding protein by cation exchange chromatography. The present invention provide a method for isolating and purifying a calcium ion-binding protein in a simple and efficient manner from a liquid sample containing a calcium ion-binding protein and contaminants without any pretreatment such as addition of a chelating agent. More specifically, the present invention relates to a method for purifying a calcium ion-binding protein which comprises contacting said protein with a cation exchange carrier in the presence of calcium ions to let the said protein be adsorbed to the carrier, and after washing, eluting said protein, and to a calcium ion-binding protein having substantially no contaminants obtained by the method of the present invention.Type: ApplicationFiled: March 21, 2002Publication date: November 14, 2002Inventors: Hiroshi Mizokami, Shinichi Furukawa, Keishin Sugawara, Tatsufumi Onchi, Kazuhiro Komatsu, Satoshi Koyanagi, Hideo Yoshizaki
-
Patent number: 6139838Abstract: The present invention provides a t-PA medicinal preparation obtained by remarkably improving the solubility and stability of t-PA or modified t-PA. Nicotinamide or a derivative thereof is incorporated into t-PA or modified t-PA-containing solvent system. If necessary, a citrate buffer solution is also used. The t-PA-containing medicinal composition is in the form of, for example, a freeze-dried preparation.Type: GrantFiled: September 5, 1997Date of Patent: October 31, 2000Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Kazuyuki Nakashima, Yoshitaka Tajima, Shinichi Furukawa, Hiroshi Mizokami
-
Patent number: D503381Type: GrantFiled: July 21, 2003Date of Patent: March 29, 2005Assignee: Denyo Co., Ltd.Inventors: Hiroshi Mizokami, Koji Suga